Caelyx Adjuvant in Elderly Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00284336|
Recruitment Status : Completed
First Posted : January 31, 2006
Last Update Posted : December 9, 2014
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Elderly||Drug: Caelyx Drug: endoxan||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label Phase II Trial to Investigate the Cardiac Effects of Pegylated Liposomal Doxorubicine (Caelyx) in Elderly Breast Cancer Patients With New Imaging and Biochemical Techniques.|
|Study Start Date :||January 2006|
|Study Completion Date :||April 2007|
- Investigate the effect on cardiac strain rate imaging (SRI) of Caelyx
- The relation between cardiac SRI and classical ejection fraction measurement.
- The relation between strain rate and blood markers such as troponin-I and BNP
- To assess the tolerability of Caelyx containing regimens in elderly breast cancer patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00284336
|Gent, Belgium, 9000|
|Leuven, Belgium, 3000|
|Principal Investigator:||hans wildiers, MD PhD||UH gasthuisberg Leuven|